Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

118.39 -2.33 (-1.93%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
65 66 Next >
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Wednesday, June 15
Reuters Warner Bros Discovery To Undergo Major Global Ad Sales Team Restructuring 
Via Benzinga
FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report
Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17. 
Via Benzinga
BioNTech Whale Trades For June 10
A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades. 
Via Benzinga
Short Volatility Alert: BioNTech SE
On Friday, shares of BioNTech SE (NASDAQ: BNTX) experienced volatile short activity. After the activity, the stock price went down -0.42% to $157.70. The overall sentiment... 
Via Benzinga
EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters
Via Benzinga
Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters
Via Benzinga
IBD/TIPP Poll: There's Bad News For Novavax's Covid Vaccine
Here's why its protein-based shot could struggle in the U.S. 
Via Investor's Business Daily
Moderna's Pediatric Covid Shot Is On Deck At The FDA: Here's What To Know
The FDA's vaccine experts will later vote on whether to recommend the shot. 
Via Investor's Business Daily
FDA Backs Pediatric Covid Shots; Here's Why Pfizer, Moderna Shares Crumbled
The FDA says Covid shots for children under the age of 5 are safe and effective. 
Via Investor's Business Daily
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, June 13
CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why 
Via Benzinga
Moderna's COVID-19 Vaccine Shows Safety, Effectiveness For Children Under 17 Years
Via Benzinga
Pfizer/BioNTech's Three-Dose COVID-19 Vaccine Safe, Effective In Younger Kids
According to the FDA briefing document, Pfizer Inc (NYSE: PFE) -BioNTech's SE (NASDAQ: 
Via Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Thursday, June 9
Reuters Blackstone Closes In Crown Bid After Australia Approvals: Reuters 
Via Benzinga
US Schedules Covid-19 Vaccines For Children Below Five Years
Via Benzinga
HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated
HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks. 
Via Benzinga
What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US
After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief. 
Via Benzinga
COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters
Via Benzinga
Pfizer To Boost Production Of Oral COVID-19 Pill With $120M Michigan Investment
Pfizer, Inc. (NYSE: PFE) is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States. 
Via Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Thursday, June 2
Reuters 
Via Benzinga
Why The FDA Isn't The Battleground For Pfizer's, Moderna's Pediatric Covid Shots
FDA's OK is just step one. Then Pfizer and Moderna need to get parents on board. 
Via Investor's Business Daily
Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five
Via Benzinga
Jim Cramer Shares His Opinion On Roblox, Century Aluminum And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he can’t recommend Roblox Corp (NASDAQ: RBLX) as it is not making money. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited... 
Via Benzinga
7 of the Best Cheap Stocks to Buy for the Second Half of 2022
These are the best cheap stocks to invest in now. They all offer compelling buying opportunities in today's volatile market. 
Via InvestorPlace
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.